FDA Removes 12 Peptides from Category 2: What It Means for Patients

You're three weeks into a peptide protocol that's actually working. Your sleep is better, your energy has shifted, your provider is pleased with your labs. Then you open Instagram and see a post that says, "The FDA just banned peptides." Your stomach drops. You screenshot it. You text your friend. You start Googling.

We've seen this exact scenario play out hundreds of times over the past few weeks — in DMs, in patient portals, in the worried questions flooding wellness forums. And most of what's circulating right now is incomplete, exaggerated, or just plain wrong.

So let's slow down. This article will explain what the FDA actually did, which peptides are affected, what it means for patients like you, and what — if anything — you need to do right now. No panic. No spin. Just clarity.

First, a Quick Refresher: What Is FDA Peptide Categorization — and Why Does It Matter?

What Are Peptides, in Plain Language?

Peptides are short chains of amino acids — the same building blocks that make up proteins. They act as signaling molecules in your body, telling cells what to do: repair tissue, release a hormone, ramp up immune function, modulate inflammation.

They're not hormones, though they can influence hormonal pathways. They're not steroids. They're not synthetic drugs in the traditional sense. Many peptides are bioidentical to molecules your body already produces — just delivered in therapeutic doses.

Their role in women's health has expanded significantly over the past decade: metabolic support, skin repair, immune modulation, hormonal balance, gut healing, and more. If you want a deeper primer, our peptide therapy for women guide covers the clinical basics.

How the FDA's Category System for Compounded Peptides Works

Most peptide therapy patients receive their prescriptions from compounding pharmacies — specialized pharmacies that prepare customized medications. The FDA distinguishes between two types: 503A pharmacies (which compound individual prescriptions based on a specific patient's order) and 503B outsourcing facilities (which can produce larger batches without patient-specific prescriptions).

To determine which substances these pharmacies can legally compound, the FDA created a categorization system:

• Category 1: Bulk drug substances that may be used in compounding under certain conditions.
• Category 2: Substances under active FDA review — a provisional, "wait-and-see" list. Compounders could continue producing these while the FDA evaluated them.
• Category 3: Substances the FDA has determined cannot be used in compounding.

Category 2 was significant because it gave compounding pharmacies a temporary pathway to keep producing peptides that lacked formal FDA approval as standalone drugs. But Category 2 status was never an endorsement. It was a regulatory holding zone — not a green light. This system has been evolving since the FDA's 2023–2024 review cycle, and the 2025 changes are a direct result of that ongoing process.

What Just Happened: The 12 Peptides the FDA Removed from Category 2

Which Peptides Were Affected?

The FDA's 2025 decision removed 12 specific peptides from Category 2, effectively closing the compounding pathway that had kept them available. Several of these are widely used in women's health and wellness protocols.

If you recognize names on this list from your own protocol, keep reading — we'll cover exactly what to do in the next section.

What Does "Removed from Category 2" Actually Mean?

This distinction matters. Reclassification is not prohibition. The FDA didn't declare these 12 peptides dangerous. It decided that the evidence supporting their use in compounding didn't meet the threshold to remain on the provisional list.

What happens next varies by peptide. Some could eventually move to Category 1 if additional data supports their safety profile. Others could enter a formal FDA drug-approval track — a longer, more expensive process. And some may effectively lose compounding access altogether if no pharmaceutical company pursues approval.

One thing to be clear about: individual patients are not in legal jeopardy. This decision affects pharmacy and prescriber compliance, not you personally.

Why Did the FDA Make This Move Now?

The Official Rationale

The FDA's stated reasoning centers on insufficient clinical evidence supporting the safety and efficacy of these peptides in their compounded forms. According to the agency's guidance on bulk drug substances used in compounding, each substance on the Category 2 list must demonstrate adequate evidence of safety and a documented history of clinical use. The FDA concluded that these 12 peptides didn't meet that bar.

This is part of a broader regulatory trend. Since 2020, the FDA has increased its scrutiny of the compounding industry — driven in part by quality-control concerns and the rapid expansion of telehealth-based prescribing during and after the COVID-19 pandemic.

The Bigger Picture: Peptides Are Growing — and Regulators Are Paying Attention

The peptide therapy market has expanded at a pace that regulators couldn't ignore. FDA oversight tends to follow market growth, and peptides hit that inflection point in 2024.

If this feels familiar, it should. The same dynamic played out with compounded semaglutide and tirzepatide (the GLP-1 receptor agonists behind Ozempic and Mounjaro). When demand surged, the FDA moved to tighten compounding access. According to a 2024 FDA statement on compounded semaglutide, the agency's primary concern was ensuring that compounded versions met the same quality standards as FDA-approved products.

The peptide reclassification follows a similar logic. This is regulatory maturation — the system catching up to a market that grew faster than oversight could keep pace.

What This Means If You're Currently a Peptide Therapy Patient

"Will My Prescription Be Affected?"

The honest answer: it depends on which peptide or peptides you're currently using.

• If your peptide is on the 12-peptide list: Your pharmacy or provider will need to transition your protocol. This doesn't mean your care stops — it means the specific compounded product you've been receiving needs to be reassessed. Contact your care team.
• If your peptide is not on the list: Your treatment is likely unaffected for now. But stay in communication with your provider, because the FDA's review process is ongoing, and additional changes could come later in 2025.

Regulatory transitions have timelines. Pharmacies don't shut down overnight. You have time to work with your provider on next steps.

"Is It Still Safe to Be on Peptide Therapy?"

"What Should I Do Right Now?"

1. Don't panic or abruptly stop treatment. Stopping a prescribed protocol without clinical guidance can cause its own problems.
2. Check which peptide(s) you're currently prescribed against the 12-peptide list above.
3. Reach out to your Amie provider (or your prescribing clinician) with questions. They've already been briefed on this change.
4. Be cautious of "gray market" alternatives. When legitimate channels tighten, unregulated sources fill the gap. Peptides purchased from research chemical sites, overseas suppliers, or social media sellers carry real risks — unknown purity, incorrect dosing, no clinical oversight.
5. Stay informed. Bookmark this page. We'll update it as new FDA guidance is released.

What Legitimate Providers and Pharmacies Are Doing in Response

How Responsible Telehealth Platforms Are Adapting

Reputable providers aren't scrambling — they're executing. The best clinical teams anticipated regulatory tightening and had contingency plans in place before the announcement.

Here's what responsible adaptation looks like right now:

• Auditing all active patient protocols against the updated FDA list
• Coordinating with compounding pharmacies (both 503A and 503B) to confirm updated formularies
• Proactively contacting patients on affected peptides before patients have to ask
• Identifying clinically appropriate alternatives where they exist

What Amie Patients Can Expect

Our clinical team is reviewing all active protocols in light of this update. If you're an Amie patient currently prescribed one of the 12 affected peptides, your provider will reach out to you directly to discuss your options and any necessary adjustments.

Amie partners only with licensed, FDA-compliant compounding pharmacies — and that commitment hasn't changed. Your care doesn't stop. It adapts.

The Nuanced Truth: Why This Ruling Has the Wellness World Divided

The Case for Tighter Regulation

There are real, patient-centered arguments in favor of what the FDA did:

• Quality control. Compounded peptides vary in purity and potency depending on the pharmacy. A 2023 study published in the Journal of the American Pharmacists Association found that compounded preparations frequently deviated from labeled potency, raising legitimate safety questions. More oversight can protect patients from substandard products.
• Evidence gaps. Several peptides on the list — particularly Epithalon, DSIP, and Dihexa — have limited peer-reviewed clinical data in humans. The research that does exist often comes from animal models or small, non-randomized studies.
• Long-term access. Regulatory clarity can actually expand patient access over time by creating formal approval pathways. If a peptide goes through FDA approval, it gains insurance coverage potential, standardized dosing, and manufacturing quality requirements.

The Concerns Worth Acknowledging

And there are real, patient-centered arguments against the timing and scope of this decision:

• Lived patient experience. Thousands of patients — including many women dealing with gut issues, autoimmune conditions, chronic inflammation, and hormonal disruption — experienced meaningful clinical improvement on peptides like BPC-157 and Thymosin Beta-4. Their experience is real, even if large-scale RCTs don't yet exist.
• International precedent. Critics point out that the FDA's evidence thresholds don't account for decades of clinical use in countries like Russia (where Semax and Selank have been prescribed medications for years) or the broader global peptide research community.
• Unintended consequences. When legitimate channels close, patients turn to unregulated sources. This is a genuine safety concern — and one that the FDA's decision may inadvertently worsen.

Amie's Position

We respect regulatory oversight and comply fully with FDA guidance. We also believe in continued research and expanded clinical pathways for peptide therapies that show real promise. Our role isn't to take political sides in a regulatory debate. It's to help you make informed decisions about your health — with clarity, not alarm.

Peptides That Are Not Affected — and What That Means for Your Options

Peptides Still Available Through Compounding

The FDA's decision targeted 12 specific peptides. Many others remain on the Category 2 list or have other legal compounding pathways. Examples that remain accessible through compliant compounding pharmacies (as of this writing) include:

• Thymosin Alpha-1 — immune modulation
• PT-141 (Bremelanotide) — sexual health (also available as the FDA-approved drug Vyleesi)
• AOD 9604 — metabolic support
• Pentosan Polysulfate — bladder and joint health

Important caveat: Availability varies by state, pharmacy, and ongoing regulatory updates. This list reflects the status at the time of publication and may change.

FDA-Approved Peptide-Based Medications

Separately, there are FDA-approved medications that are peptide-based and completely unaffected by this compounding decision:

• GLP-1 receptor agonists (semaglutide, tirzepatide) — metabolic and weight management
• Oxytocin — labor induction, postpartum support
• Certain growth factors used in dermatology and wound care

These may be relevant alternatives for some patients, depending on your treatment goals.

What to Discuss With Your Provider

This isn't a "figure it out on your own" situation. Whether you need to switch peptides, adjust dosing, or explore a completely different therapeutic approach, those are clinical decisions that belong in a conversation with a licensed provider — not on a subreddit.

A good provider will review your health goals, your current labs, and the available options, then make a recommendation grounded in your specific situation. If you'd like to talk to a provider about your peptide therapy options, that's exactly what our clinical team is here for.

Frequently Asked Questions

The Bottom Line

You deserve to understand what's happening in your own healthcare — not to piece it together from alarming Instagram posts and conflicting Reddit threads. If a peptide protocol was working for you and this change disrupts it, that frustration is valid.

But this is also part of a maturing field. Peptide therapy is moving from a niche corner of functional medicine into the mainstream, and with that growth comes the kind of regulatory attention that — when done well — protects patients and raises the standard of care.

If you have questions about your current protocol, the best place to start is with your provider. And if you want to understand peptide therapy from the ground up — what works, what the evidence supports, and what makes sense for women specifically — start with our complete guide to peptide therapy for women.

At Amie, we'll keep you informed as this story develops. This page will be updated as new FDA guidance is released.

Author: Amie Editorial Team | Medical Review: Dr. Erin Meyer, MD, Internal Medicine

Last updated: June 2025. This article reflects FDA guidance current at the time of publication. Regulatory changes may occur after this date — consult your provider and check FDA.gov for the latest updates.

Written by

Dr. Erin Meyer, MD, Internal Medicine

MD, Internal Medicine

Dr. Meyer is board-certified in internal medicine with a focus on longevity, peptide therapy, and integrative approaches to aging.